Oncolytics Biotech Inc T.ONC

Seagen's top ADC defeated by BMS checkpoint inhibitor

[Noteable]

June 03, 2023 - Compared with Adcetris, Bristol Myers Squibb’s Opdivo significantly reduced the risk of cancer progression or death by 52% in adults and children with newly diagnosed stage 3 or 4 classical Hodgkin lymphoma, according to phase 3 data unveiled at the 2023 American Society of Clinical Oncology annual meeting. Both drugs were used on top of the AVD regimen of chemotherapy.

https://www.fiercepharma.com/pharma/seagens-top-selling-drug-under-threat-bristol-myers-opdivo-beats-adcetris-lymphoma

[Noteable]

" Bristol’s blockbuster Opdivo halted the progression of advanced Hodgkin’s lymphoma in 94% of patients who also received chemotherapy, compared with 86% of those who received Seagen’s Adcetris plus the standard treatment. Four patients who received Opdivo died during the one-year study of 976 people, versus 11 who took Adcetris, according to findings released Sunday at the American